These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16185904)

  • 1. A chemometric study of phosphodiesterase 5 inhibitors.
    de O Figueiredo LJ; Garrido FM; Kunisawa VY; Aboim CE; Licks OB
    J Mol Graph Model; 2006 Jan; 24(4):227-32. PubMed ID: 16185904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
    Pissarnitski D
    Med Res Rev; 2006 May; 26(3):369-95. PubMed ID: 16388517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase--basic and potential clinical applications.
    Hidaka H; Endo T
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():245-59. PubMed ID: 6144253
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
    Srivani P; Srinivas E; Raghu R; Sastry GN
    J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
    Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
    Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
    Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema.
    Bates MG; Thompson AA; Baillie JK
    Curr Opin Investig Drugs; 2007 Mar; 8(3):226-31. PubMed ID: 17408118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
    Jiang W; Alford VC; Qiu Y; Bhattacharjee S; John TM; Haynes-Johnson D; Kraft PJ; Lundeen SG; Sui Z
    Bioorg Med Chem; 2004 Mar; 12(6):1505-15. PubMed ID: 15018924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 5 phosphodiesterase inhibition: the focus shifts to the heart.
    Semigran MJ
    Circulation; 2005 Oct; 112(17):2589-91. PubMed ID: 16246958
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioactivities of a series of phosphodiesterase type 5 (PDE-5) inhibitors as modelled by MIA-QSAR.
    Antunes JE; Freitas MP; Rittner R
    Eur J Med Chem; 2008 Aug; 43(8):1632-8. PubMed ID: 18045743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.
    Beghyn T; Hounsou C; Deprez BP
    Bioorg Med Chem Lett; 2007 Feb; 17(3):789-92. PubMed ID: 17107795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.
    Yang GF; Lu HT; Xiong Y; Zhan CG
    Bioorg Med Chem; 2006 Mar; 14(5):1462-73. PubMed ID: 16263288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Rosen RC; Shaw JW
    Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
    [No Abstract]   [Full Text] [Related]  

  • 18. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
    Giovannoni MP; Vergelli C; Biancalani C; Cesari N; Graziano A; Biagini P; Gracia J; Gavaldà A; Dal Piaz V
    J Med Chem; 2006 Aug; 49(17):5363-71. PubMed ID: 16913726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confirmation of tyrosine 698 in beta subunit of cGMP phosphodiesterase in patients with retinitis pigmentosa and population of the west of Mexico.
    Núñez-Gutiérrez IC; García-Cruz D; Fragoso-Herrera R; Medina-Lozano C
    Rev Invest Clin; 2006; 58(4):359-61. PubMed ID: 17146947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.